Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence

Abstrakt

Lenalidomide (Len) maintenance remains the cornerstone of multiple myeloma (MM) treatment in patients after upfront autologous stem cell transplantation. Yet the data about the benefit of Len monotherapy in high-risk patients remains questioned.

Here we aimed on describing the benefit of Len maintenance in subgroups of patients defined by the novel R2-ISS risk stratification system.